Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Acute Myeloid Leukemia
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Cytarabine
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Other: Pharmacological Study

First Posted Date: 2010-11-29

Last Posted Date: 2017-09-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT01249430

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation

Phase 3

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Etoposide
Drug: All-trans retinoic acid (ATRA)

First Posted Date: 2010-11-10

Last Posted Date: 2018-08-01

Lead Sponsor: University of Ulm

Target Recruit Count: 144

Registration Number: NCT01237808

Locations: 🇩🇪
Ubbo-Emmius Klinik Aurich, Aurich, Germany
🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Medizinische Universitätsklinik, Freiburg, Germany

and more 30 locations

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Phase 3

Active, not recruiting

Conditions: Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Peripheral Primitive Neuroectodermal Tumor of Bone
Localized Extraskeletal Ewing Sarcoma

Interventions: Drug: Cyclophosphamide
Drug: Dexrazoxane
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Vincristine Sulfate
Drug: Topotecan Hydrochloride

First Posted Date: 2010-11-01

Last Posted Date: 2023-08-31

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 642

Registration Number: NCT01231906

Locations: 🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸
Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 240 locations

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: NSCLC
Non-small Cell Lung Cancer
Lung Cancer

Interventions: Radiation: Stereotactic boost
Radiation: Conventional RT
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2010-10-18

Last Posted Date: 2015-06-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1

Registration Number: NCT01222572

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Phase 2

Terminated

Conditions: Leukemia
Acute-graft-versus-host Disease
Non-Hodgkin Lymphoma (NHL)
Hodgkin Lymphoma
Hematologic Diseases

Interventions: Drug: Sirolimus
Drug: Mycophenolate mofetil (MMF)
Drug: Carmustine
Drug: FTBI
Drug: Etoposide
Drug: Cyclophosphamide (Cyclo, CY)

First Posted Date: 2010-10-13

Last Posted Date: 2017-06-05

Lead Sponsor: Stanford University

Target Recruit Count: 3

Registration Number: NCT01220297

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Lenalidomide
Drug: Oxaliplatin
Drug: Rituximab
Drug: Etoposide

First Posted Date: 2010-09-09

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 111

Registration Number: NCT01197560

Locations: 🇺🇸
Washington University Siteman Cancer Center, Saint Louis, Missouri, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Australia

and more 54 locations

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Phase 1

Completed

Conditions: Ann Arbor Stage I Grade 3 Follicular Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
AIDS-Related Plasmablastic Lymphoma
AIDS-Related Primary Effusion Lymphoma
Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Vorinostat

First Posted Date: 2010-09-02

Last Posted Date: 2023-11-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT01193842

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 32 locations

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

Not Applicable

Completed

Conditions: AML

Interventions: Drug: Sirolimus
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2010-08-19

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 36

Registration Number: NCT01184898

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: Azacitidine
Drug: Lenograstim

First Posted Date: 2010-08-12

Last Posted Date: 2020-12-31

Lead Sponsor: University of Ulm

Target Recruit Count: 277

Registration Number: NCT01180322

Locations: 🇦🇹
Universitätsklinikum Innsbruck, Innsbruck, Austria
🇩🇪
Universitätsklinikum Schleswig-Holstein, Kiel, Germany
🇦🇹
Krankenhaus der Barmherzigen Schwestern, Linz, Austria

and more 40 locations

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: midostaurin
Drug: Bortezomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2010-08-04

Last Posted Date: 2016-07-06

Lead Sponsor: Alison Walker

Target Recruit Count: 34

Registration Number: NCT01174888

Locations: 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy